OPTUM VENTURES TRIAL
OPTUM VENTURES SERIES

She was selected to the Forbes 30 Under 30 list in 2015. Isabelle began her career as an investment banker in Hong Kong and graduated from the University of Pennsylvania. The firm prefers to invest in the digital health. Before Capsule, she worked at beloved consumer brands in London and New York. Founded in 2017, Optum Ventures is a corporate venture capital arm of Optum based in Boston, Massachusetts. Prior to Calibrate, Isabelle led business operations, growth, and strategic partnerships & communications at Capsule, a technology business rebuilding the pharmacy from the inside out. Calibrate was recognized as a World Economic Forum Technology Pioneer in 2021 and by Fast Company’s World Changing Ideas in 2022.

OPTUM VENTURES TRIAL

In two years, Calibrate has raised more than $125 million from leading investors, including Founders Fund, Tiger Global, Optum Ventures, Forerunner Ventures, Threshold Ventures, and Redesign Health, and has published clinically-reviewed results from its One-Year Metabolic Reset that exceeded clinical trial outcomes across metabolic markers. The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.Isabelle Kenyon is the Founder & CEO of Calibrate, a metabolic health company on a mission to change the way the world treats weight. Informing, connecting, and transforming the global corporate venture capital ecosystem. Veroneau also sits on the Board of Overseers for Brigham and Women’s Hospital. And through the power of partnership, we’re putting people first and spearheading what’s next for the industry. Truly remarkable care solutions are needed now more than ever. Investing in transformational people and ideasit's what we do.

There, she focused on its innovation pipeline, which is mostly concentrated on emerging companies and international markets. Approach How Well Gets Done Making health care betterit’s why we get up in the morning. Veroneau started her career running product development at a healthcare startup serving health plans, hospitals and employers before transitioning to the corporate strategy team at UnitedHealth Group.

OPTUM VENTURES SERIES

Among its recent investments are a role in the $75m series D raise for Cortica, provider of neurological therapies for children, participation in the $13m series B round for virtual-reality therapy ﬁrm BehaVR and involvement in the £330m series E round for DispatchHealth, a provider of mobile and virtual healthcare in domestic settings. Optum Ventures has invested more than $600m since it was founded. She has led notable investments such as AbleTo, a US-based virtual healthcare developer that raised $57.4m in a series A round in 2017, and US-based healthcare and social service network provider Unite Us, which raised $195.6m. The unit is an early-stage investment ﬁrm focused on emerging healthcare technology and analytics She was promoted to managing partner in March 2022 having spent the previous ﬁve years as principal, senior principal and then, from January 2020, as partner. Veroneau manages Optum Ventures alongside Larry Renfro, who also works as vice chairman of UnitedHealth. The unit is an early-stage investment ﬁrm focused on emerging healthcare technology and analytics. Laura Veroneau is the managing partner and founding team member of Optum Ventures, the corporate venturing arm of pharmacy beneﬁt manager Optum, which is part of UnitedHealth Group.

Laura Veroneau, managing partner of Optum Ventures, is one of the 100 leading corporate venturing professionals in our Powerlist this year.

Optum ventures